Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 299Carboplatin 229Cisplatin 159Gemcitabine 152Paclitaxel 151Pemetrexed 121Bevacizumab 121Docetaxel 106Oxaliplatin 82durvalumab 81Nivolumab 81Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 77130-nm albumin-bound paclitaxel 73Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 56fludarabine 51Lenalidomide 50venetoclax 46Prednisone 45Letrozole 42Irinotecan 42enzalutamide 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × C188-9 compound × 90 days × Clear all
NCT05440708 2026-04-27

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Tvardi Therapeutics, Incorporated

Phase 1/2 Recruiting
193 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡